. 2022 Dec 1;12(12):e1104. doi: 10.1002/ctm2.1104

TABLE 4.

Positive effects of candidate genes on bleeding and the pharmacodynamics of dabigatran

SNP	Gene	Bleeding 1 month	Bleeding 6 months	Bleeding 12 months	Bleeding 24 months	FIIa (ng/ml)	FAPTT (s)	FPT (s)	GIIa (ng/ml)	GAPTT (s)	GPT (s)
SNP	Gene	p‐Values
rs2235013^a	ABCB1	0.102	0.572	0.396	0.112	0.021	0.087	0.094	0.496	0.430	0.786
rs2235033^a	ABCB1	0.102	0.572	0.396	0.112	0.021	0.087	0.094	0.496	0.430	0.786
rs2273697 ^a	ABCC2	/	0.249	0.701	0.990	0.598	0.441	0.426	0.052	0.286	3.10E‐06
rs4148395 ^a	ABCC2	/	0.249	0.701	0.990	0.598	0.441	0.426	0.052	0.286	3.10E‐06
rs2231142 ^b	ABCG2	0.352	0.691	0.273	0.227	0.111	0.017	0.016	7.21E‐03	1.79E‐03	0.705
rs2231148 ^a	ABCG2	0.683	0.568	0.892	0.960	0.201	0.083	0.032	0.028	0.811	0.129
rs2231156 ^a	ABCG2	0.165	0.823	0.782	0.457	0.222	0.030	0.118	5.96E‐04	3.91E‐03	0.559
rs2231165 ^a	ABCG2	0.242	7.07E‐03	0.083	0.049	0.921	0.219	0.823	0.605	0.021	0.457
rs112236246 ^a	CES1	0.758	0.902	0.427	0.454	0.322	0.283	0.783	0.150	0.028	0.027
rs2244614 ^a	CES1	0.763	0.910	0.441	0.348	0.342	0.459	0.925	0.157	0.040	0.025
rs3217164 ^a	CES1	0.763	0.910	0.441	0.348	0.342	0.459	0.925	0.157	0.040	0.025
rs4646427 ^a	CYP1A2	0.259	0.084	0.435	0.449	0.161	0.097	0.037	0.517	0.625	0.558
rs8192720 ^a	CYP2A6	0.222	0.081	0.017	0.030	0.621	0.905	0.788	0.697	0.958	0.340
rs8192726 ^a	CYP2A6	0.441	0.797	0.136	0.018	0.293	0.584	0.944	0.457	0.142	0.605
rs8192719 ^a	CYP2B6	0.667	0.991	0.632	0.944	0.286	0.931	0.708	0.023	0.419	0.654
rs3745275 ^a	CYP2B6, CYP2A13	0.690	0.419	0.183	0.210	0.014	0.602	0.274	0.251	0.156	0.904
rs3745276 ^a	CYP2B6, CYP2A13	0.494	0.172	0.028	0.068	0.643	0.850	0.840	0.795	0.306	0.647
rs3745277 ^a	CYP2B6, CYP2A13	0.041	0.141	0.159	0.984	0.459	0.048	0.119	0.696	0.738	0.832
rs7249735 ^a	CYP2B6, CYP2A13	0.835	0.378	0.246	0.122	0.011	0.638	0.240	0.124	0.270	0.945
rs1058932 ^a	CYP2C8	0.580	0.235	0.126	0.099	0.515	0.832	0.603	0.148	0.923	0.011
rs11572078 ^a	CYP2C8	0.580	0.235	0.126	0.099	0.515	0.832	0.603	0.148	0.923	0.011
rs2275622 ^a	CYP2C8	0.983	0.628	0.241	0.208	0.339	0.882	0.875	0.259	0.997	0.016
rs17847029	CYP2C9	0.141	0.813	0.701	0.453	0.043	0.083	0.088	0.931	0.882	0.860
rs3738474	CYP2J2	0.035	0.111	0.234	0.538	0.940	0.809	0.718	0.854	0.648	0.737
rs11937525	FRAS1	0.184	0.334	0.819	0.855	0.289	0.259	0.120	0.182	0.398	0.023
rs17003071	FRAS1	0.945	0.704	0.0492	0.199	0.566	0.893	0.897	0.713	0.465	0.298
rs17003160	FRAS1	0.261	0.753	0.759	0.680	0.633	0.553	0.538	0.678	0.935	0.028
rs398092530	FRAS1	0.242	0.858	0.619	0.552	0.569	0.532	0.381	0.923	0.919	0.039
rs1062677	SLC4A4	/	0.713	0.456	0.735	0.441	0.715	0.764	0.022	0.200	0.765
rs2291076 ^a	SLCO1B1	0.121	0.166	0.193	0.043	0.402	0.523	0.897	0.112	0.589	0.617
rs2306283 ^a	SLCO1B1	0.121	0.154	0.164	0.043	0.686	0.826	0.854	0.129	0.634	0.685
rs4149032 ^a	SLCO1B1	0.471	0.217	0.047	0.022	0.924	0.660	0.899	0.138	0.274	0.085
rs79527462	SULT1A1	0.599	0.999	0.527	0.176	0.083	0.471	0.053	0.013	0.179	0.630

Abbreviations: ABCB1, ATP‐binding cassette subfamily B member 1; ABCC2, ATP‐binding cassette subfamily C member 2; ABCG2, ATP binding cassette subfamily G member 2; CES1, carboxylesterase 1; CYP1A2, cytochrome P450 family 1 subfamily A member 2; CYP2A6, cytochrome P450 family 2 subfamily A member 6; CYP2B6, cytochrome P450 family 2 subfamily B member 6; CYP2A13, cytochrome P450 family 2 subfamily A member 13; CYP2AJ2, cytochrome P450 family 2 subfamily J member 2; CYP2C8, cytochrome P450 family 2 subfamily C member 8; CYP2C9, cytochrome P450 family 2 subfamily C member 9; SLC4A4, solute carrier family 4 member 4; SLCO1B1, solute carrier organic anion transporter family member 1B1; SULT1A1, sulfotransferase family 1A member 1.

^{^a}

The SNP was detected and analyzed for variations associated with the pharmacodynamics in reported pharmacogenomic studies of dabigatran.

^{^b}

The SNP was detected and analyzed for variations associated with bleeding in reported pharmacogenomic studies of dabigatran.